- Home
- OWLS vs HQL Comparison
OWLS vs HQL Comparison
Compare OWLS & HQL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OWLS | HQL |
|---|---|---|
| Founded | 2010 | 1992 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Investment Managers |
| Sector | Technology | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 534.7M | 490.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | OWLS | HQL |
|---|---|---|
| Price | $5.78 | $16.20 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 15.4K | ★ 105.3K |
| Earning Date | 12-29-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.56% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.79 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $20.54 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.15 | $10.55 |
| 52 Week High | $29.00 | $17.80 |
Technical Indicators
Market Signals| Indicator | OWLS | HQL |
|---|---|---|
| Relative Strength Index (RSI) | 47.63 | 42.05 |
| Support Level | $5.93 | $15.66 |
| Resistance Level | $6.20 | $17.51 |
| Average True Range (ATR) | 0.15 | 0.31 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 62.21 | 41.27 |
Price Performance
Historical ComparisonAbout OWLS OBOOK Holdings Inc.
OBOOK Holdings Inc is focused on using blockchain technology to provide inventive solutions to customers in various sectors, including financial services, hospitality, and e-commerce. Through its e-commerce, hospitality and payments offerings, it is committed to serving businesses and individuals whose commercial activities involve cross-border transactions.
About HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.